NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ABM Therapeutics

ABM Therapeutics

Private
ShanghaiHealthcare & Life Scienceshttp://www.abmtx.com/

Last Round

Series B

Extension

May 4, 2023

Total Funding Raised

$50M

Company Overview

ABM Therapeutics is a clinical-stage biopharmaceutical company that develops small molecule targeted therapies for the treatment of brain cancer and cancer metastases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

small molecule therapytargeted cancer therapyblood-brain barrierbrain-penetrant drugsBRAF inhibitorglioblastomabrain metastasesprecision oncologyoncology drug developmentCNS oncologydrug discovery platformkinase drug discoveryclinical-stage biopharmaMEK inhibitorHPK1 inhibitorOrphan Drug DesignationFast Track Designation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ABM Therapeutics Comparables

Compare ABM Therapeutics with similar companies based on industry and business-model similarity.

ABM Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Black Diamond Therapeutics
78%
Servier
76%
Suzhou NeuPharma Co., Ltd.
75%

ABM Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionMay 4, 2023
Series BJan 4, 2022
Series AAug 7, 2020

Key People

Founding team and executive leadership

Chen Chen

Chief Executive Officer

Executive Team

ABM Therapeutics Investors

Notable investors and investment history

ABM Therapeutics investors
InvestorRounds
HighLight CapitalSeries B
Baidu VenturesSeries B
Photon FundSeries B
Sincere CapitalSeries B
Jiangsu Honghui Equity Investment ManagementSeries B
Kaitai CapitalSeries A
健壹资本Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 4, 2022

    $30M round led by Photon Fund and HighLight Capital

  • Aug 7, 2020

    $20M round led by 华创资本.

ABM Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ABM Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ABM Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range5
Year Founded2015
Last FundingMay 4, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.